NUVB Stock: Nuvation Bio Inc. Stock Price, Analysis & Insights
Get live nuvb stock price $7.15, comprehensive Nuvation Bio Inc. stock analysis, charts, news, and expert forecast. Real-time nuvb stock data and investment insights.
Loading chart...
Company Overview
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Company Information
- CEO
- David T. Hung
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 273
Contact Information
- Website
- https://www.nuvationbio.com
- Address
- 1500 Broadway
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 1.64)
Business Model & Strategy
Nuvation Bio Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO David T. Hung, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Nuvation Bio Inc. competes in the Biotechnology within the broader Healthcare. With 2.4 billion in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the New York Stock Exchange, Nuvation Bio Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Nuvation Bio Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Nuvation Bio Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Nuvation Bio Inc.
- ⚠Investors should consider how Nuvation Bio Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
2.44B
P/E Ratio
-14.59
Beta
1.64
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 2.44B market capitalization
- Trading Volume: 58.13M shares traded today
- Price Range: 52-week range of $1.54 - $7.35
- Exchange: Listed on New York Stock Exchange
Financial Metrics
Market Analysis for Nuvation Bio Inc.
Nuvation Bio Inc. (NUVB) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 2.44B, the company represents a significant player in its market. The stock is currently trading at $7.15 with a positivedaily change of 49.11%.
The company's 273 employee base and presence on the New York Stock Exchangeexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -14.59, beta of 1.64, and 52-week price range from $1.54 to $7.35when evaluating investment opportunities.
Why Invest in Nuvation Bio Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (New York Stock Exchange)
- • Experienced leadership under David T. Hung
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.